Tumor-targeted MMAE (ADC or ACPP conjugate) combined with IR increased tumor immune infiltration of CD45 + , CD8 + T-cells, macrophages and neutrophils, compared to IR or MMAE alone. The gene discussed is CD8A; the disease is neoplasm.